• 1. EWOD-driven droplet microfluidic device integrated with optoelectronic tweezers as an automated platform for cellular isolation and analysis?
  Gaurav J. Shah,Eric P.-Y. Chiou,Ming C. Wu,Chang-Jin “CJ” Kim Lab Chip, 2009,9, 1732-1739
• 2. Evolution of dealloying induced strain in nanoporous gold crystals?
  Ross Harder,David C. Dunand,Ian McNulty Nanoscale, 2017,9, 5686-5693
• 3. Estimates of hydride ion stability in condensed systems: energy of formation and solvation in aqueous and polar-organic solvents
  Craig A. Kelly,David R. Rosseinsky Phys. Chem. Chem. Phys., 2001,3, 2086-2090
• 4. Evolution in surface coverage of CH3NH3PbI3?XClXvia heat assisted solvent vapour treatment and their effects on photovoltaic performance of devices
  Dhirendra K. Chaudhary,Pramendra Kumar,Lokendra Kumar RSC Adv., 2016,6, 94731-94738
• 5. Excitation dependent bidirectional electron transfer in phthalocyanine-functionalised MoS2 nanosheets?
  Christopher J. Harrison,Kyle J. Berean,Enrico Della Gaspera,Jian Zhen Ou,Richard B. Kaner,Kourosh Kalantar-zadeh,Torben Daeneke Nanoscale, 2016,8, 16276-16283

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Imidazopyridines Imidazopyridines
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Imidazopyridines

Introduction to 3,8-Dibromo-2,6-dimethylimidazo[1,2-a]pyridine (CAS No. 2413441-15-1)

3,8-Dibromo-2,6-dimethylimidazo[1,2-a]pyridine, identified by its Chemical Abstracts Service (CAS) number 2413441-15-1, is a heterocyclic compound that has garnered significant attention in the field of pharmaceutical and chemical research due to its versatile structural framework and potential biological activities. This compound belongs to the imidazopyridine class, a scaffold that has been extensively explored for its role in drug discovery. The presence of bromine atoms at the 3 and 8 positions, along with methyl groups at the 2 and 6 positions, introduces unique reactivity and functionalization possibilities, making it a valuable intermediate in synthetic chemistry.

The imidazopyridine core is a fused ring system consisting of an imidazole ring connected to a pyridine ring. This structural motif is known for its ability to interact with biological targets such as enzymes and receptors, which has led to its incorporation in numerous lead compounds for therapeutic applications. The specific substitution pattern of 3,8-Dibromo-2,6-dimethylimidazo[1,2-a]pyridine enhances its utility as a building block in medicinal chemistry. The bromine atoms, in particular, serve as versatile handles for further functionalization via cross-coupling reactions such as Suzuki-Miyaura or Buchwald-Hartwig couplings, enabling the introduction of diverse substituents at strategic positions within the molecule.

In recent years, there has been growing interest in imidazopyridines as pharmacophores due to their demonstrated efficacy in modulating various biological pathways. For instance, derivatives of this class have shown promise in the development of inhibitors targeting kinases and other enzymes implicated in cancer progression. The brominated derivatives, including 3,8-Dibromo-2,6-dimethylimidazo[1,2-a]pyridine, are particularly attractive because they can be readily modified to generate libraries of compounds for high-throughput screening. Such libraries are instrumental in identifying novel therapeutic agents with improved pharmacokinetic profiles and reduced toxicity.

One of the most compelling aspects of 3,8-Dibromo-2,6-dimethylimidazo[1,2-a]pyridine is its potential application in the synthesis of small-molecule inhibitors that disrupt protein-protein interactions. These interactions are critical for many cellular processes and are often dysregulated in diseases such as cancer and inflammatory disorders. By designing molecules that selectively bind to specific protein targets, researchers aim to develop treatments that can modulate disease pathways without affecting other biological systems. The structural features of 3,8-Dibromo-2,6-dimethylimidazo[1,2-a]pyridine, including its rigid heterocyclic core and halogenated substituents, make it an ideal candidate for generating such selective inhibitors.

The synthesis of 3,8-Dibromo-2,6-dimethylimidazo[1,2-a]pyridine typically involves multi-step organic transformations starting from readily available precursors. Common synthetic routes include cyclization reactions followed by bromination and methylation steps. Advances in synthetic methodologies have enabled more efficient and scalable production processes for this compound. For example, transition-metal-catalyzed reactions have been employed to streamline the introduction of bromine atoms and methyl groups at the desired positions. These improvements have not only enhanced the availability of 3,8-Dibromo-2,6-dimethylimidazo[1,2-a]pyridine but also reduced the cost associated with its preparation.

From a computational chemistry perspective, virtual screening techniques have been increasingly utilized to identify potential hits derived from scaffolds like imidazopyridines. Molecular docking studies can predict how 3,8-Dibromo-2,6-dimethylimidazo[1,2-a]pyridine or its derivatives might interact with biological targets based on their three-dimensional structures. These studies provide valuable insights into binding affinities and pose predictions about which modifications might enhance activity or selectivity. Such computational approaches complement experimental efforts by allowing researchers to prioritize compounds for further investigation.

The pharmacological evaluation of 3,8-Dibromo-2,6-dimethylimidazo[1,2-a]pyridine has revealed several interesting properties that warrant further exploration. Preclinical studies have demonstrated that certain derivatives exhibit anti-inflammatory effects by inhibiting key signaling pathways involved in immune responses. Additionally，some modifications have shown antiviral activity against RNA viruses by interfering with viral replication mechanisms. These findings underscore the broad therapeutic potential of imidazopyridines and highlight the importance of exploring new derivatives.

In conclusion,3,8-Dibromo-,26-dimethylimidazo\[,12-a\]pyridine (CAS No.\*\*2413441-15-1\*\*)\*\* is a structurally intriguing compound with significant applications in pharmaceutical research.\*\* Its unique substitution pattern offers opportunities for diverse chemical modifications,\*\* making it a valuable tool for developing novel therapeutic agents.\*\* The growing body\*\*of literature on imidazopyridines,\*\*including this specific derivative,\*\*suggests that it will continue\*\*to play a crucial role\*\*in drug discovery efforts aimed at addressing various diseases.\*\*

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)